Results 111 to 120 of about 142,066 (310)

Incidence of interstitial lung diseases found in previous studies.

open access: yes, 2022
Incidence of interstitial lung diseases found in previous studies.
Sahajal Dhooria (2615254)   +9 more
core   +1 more source

Mechanically Spatio‐Chimeric Fibrin Assembly Enables Vascular‐Integrated Muscle Reconstruction for Volumetric Muscle Loss Repair

open access: yesAdvanced Materials, EarlyView.
SPARC (spatio‐chimeric, plasma‐based, anisotropic, and shear‐responsive construct) that integrates myogenic and vascular microenvironments within a single construct. The dual‐modulus matrix directs aligned myotube formation and endothelial network development, enabling a vascularized muscle implant that seamlessly anastomoses with host tissue and ...
Su Hyun Jung   +6 more
wiley   +1 more source

Healthcare professionals’ perspectives on implementation of home monitoring in individuals with pulmonary fibrosis

open access: yesERJ Open Research
Introduction Home monitoring of physical parameters, symptoms and quality of life in individuals with pulmonary fibrosis (PF) could overcome gaps in clinical care by enabling early detection of disease progression, guiding patient management and ...
Delian E. Hofman   +7 more
doaj   +1 more source

Cell Adhesion by Design: Engineering Tissue Culture Scaffolds With Adhesion Cues

open access: yesAdvanced Materials Interfaces, EarlyView.
ABSTRACT In scaffold‐based tissue engineering, the matrix should provide adequate adhesion cues for cell attachment, spreading, and function. Given the multitude of adhesion receptors and the diversity of scaffolds, there are many approaches to render scaffolds adhesive, even though they are not all equivalent.
Dalia Dranseike   +3 more
wiley   +1 more source

Understanding emotional and practical challenges of initiating oxygen therapy in pulmonary fibrosis: insights from a patient-centered survey

open access: yesBMC Pulmonary Medicine
Background Pulmonary fibrosis (PF) causes respiratory insufficiency due to progressive lung scarring and impaired gas exchange. Although no curative treatment exists, pharmacological therapies may slow progression, while oxygen therapy alleviates ...
Marjolein Drent   +4 more
doaj   +1 more source

Interstitial lung diseases in a lung cancer screening trial

open access: yes, 2011
Interstitial lung diseases in a lung cancer screening trial are described usin ...
Randi G.   +8 more
core   +1 more source

Unlocking the Potential of MXene‐Based Electrochemical Biosensors: A Review of Biofunctionalization Strategies and Biosensing Principles

open access: yesAdvanced Materials Technologies, EarlyView.
ABSTRACT Electrochemical biosensors enable the accurate and timely detection of clinical biomarkers, improving healthcare and precision medicine. MXene nanosheets, a class of 2D transition metal carbides, nitrides, and carbonitrides, are promising materials for developing next‐generation electrochemical biosensors due to their unique physicochemical ...
Muhsin Ali   +4 more
wiley   +1 more source

Interstitial Lung Diseases and Non-Small Cell Lung Cancer: Particularities in Pathogenesis and Expression of Driver Mutations

open access: yes
Introduction: Interstitial lung diseases are a varied group of diseases associated with chronic inflammation and fibrosis. With the emerging and current treatment options, survival rates have vastly improved.
Foteinos-Ioannis Dimitrakopoulos   +5 more
core   +1 more source

Spatiotemporal Sequential Delivery of Chidamide Regulates Macrophage Reprogramming in Lymphoma Microenvironment Through HDACs‐STAT3 Pathway

open access: yesAdvanced Science, EarlyView.
Our study identifies the HDACs‐STAT3 axis as key regulator for M2 macrophage accumulation in DLBCL. We developed Chid@M2pep‐EVs/TP, a pH‐responsive drug delivery system for M2 macrophage specific chidamide administration. By coupling M2‐targeted chidamide with EVs‐mediated delivery, this system reprograms M2 to M1 via HDAC inhibition and STAT3 ...
Bo Dai   +15 more
wiley   +1 more source

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases

open access: yesBMC Pulmonary Medicine, 2019
Background Fibrosing, non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung diseases (fILDs) are a heterogeneous group of diseases characterized by a different amount of inflammation and fibrosis. Therapy is currently based on corticosteroids and/
Sebastiano Emanuele Torrisi   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy